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ABSTRACT 
Acne vulgaris (AV) occurs in more than 80% of dermatological cases in adolescents and young adults and affects the quality of life. Oral isotretinoin, 
a metabolite product of vitamin A, is well-known to be the most effective treatment for severe nodulocystic AV and moderate AV that does not 
respond to other therapeutic modalities. Thus, this literature review was conducted to explain the mechanism of action, effectiveness, 
contraindications, side effects, and safety of oral isotretinoin in AV, which provided essential information for dermatologists. Furthermore, 
isotretinoin is the only treatment modality that has implications for the entire pathogenesis of acne. It contributes to decreasing corneocytes’ 
adhesion, supporting cellular proliferation and follicular renewal, induction of cell apoptosis, and immune regulation. The effectiveness of AV 
therapy with isotretinoin has expanded as it is also indicated for moderate to severe AV that does not respond well to topical combination therapy 
or systemic antibiotics. However, isotretinoin is included in Category X drugs and may induce many side effects from mucocutaneous effects to 
teratogenicity. From this extensive literature review, it can be concluded that isotretinoin is one of the treatment modalities for acne with good 
effectivity due to its mechanism of actions that affect the entire acne pathogenesis. Considering the various side effects of isotretinoin, its use 
requires adequate clinical assessment and monitoring by a dermatologist.  
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INTRODUCTION 
Acne vulgaris (AV) is a broad-spectrum multifactorial disease. The 
clinical manifestations include white and black comedones, papule, 
pustule, node, and cyst [1]. Various triggering factors that have been 
identified are as follows: genetics, race, stress, diet, cosmetics, drugs, 
physical pressure, and smoking habits [2, 3]. Acne vulgaris occurs in 
more than 80% of dermatological cases in adolescents and young 
adults [2, 4]. About 20-30% of moderate to severe AV develops in 
young adults and profoundly affects their quality of life. Some adult 
patients require prolonged therapy due to its persistent characteristic. 
AV management’s general principles include detection of triggering 
factors, and combination of medications depending on pathogenesis, 
clinical condition, and psychological circumstances. AV medications 
can be adjusted according to the degree of AV severity based on 
Lehmann’s criteria, divided into mild, moderate, and severe [5]. Table 
1 outlines the recommended therapy for AV based on the American 
Academy of Dermatology (AAD) [6]. 
Adult acne vulgaris is sometimes difficult to treat, even though 
combinations of topical therapy and standard systemic antibiotics 
have been administered. The dosage of isotretinoin commonly used 
for AV is 0,5-1 mg/kg/per day for 4-6 mo. As clinical trials 
progressed, the recent trend suggests that low doses of isotretinoin 
might be effective in treating acne with a lower risk of adverse 
effects [4, 7].  
 
Table 1: Therapeutic algorithms for the management of acne vulgaris 
 Mild AV Moderate AV Severe AV  Ref 
First-line 
treatment 
Benzoyl Peroxide (BP) or 







Topical combination therapy** 
BP+antibiotic or 







retinoid+BP+topical antibiotic  
Oral antibiotic 
+topical combination therapy** 







Add topical retinoid or BP (if 





Consider topical dapsone  
Consider alternate combination 
therapy  
-or- 
Consider changes in oral 
antibiotic 
-or- 
Add combined oral 
contraceptive or oral 
spironolactone (females) 
-or- 
Consider oral isotretinoin 
Consider changes in oral 
antibiotic 
-or- 
Add combine oral contraceptive 
or oral spironolactone (females)  
-or- 
Consider oral isotretinoin 
 [6] 
**Can be prescribed as a fixed combination product or as a monotherapy. BP: benzoyl peroxide. 
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Oral isotretinoin is well-known to be the most effective treatment 
for severe nodulocystic AV and moderate AV that does not respond 
to other therapeutic modalities. Oral isotretinoin (13-cis-retinoic 
acid) is the first generation of nonaromatic retinoid beta-carotene 
(provitamin A) [8]. Oral isotretinoin was initially approved as a 
treatment for severe AV by The United States Food and Drug 
Administration (FDA) in 1982 [7] Over the next two decades, 
isotretinoin is still a clinically effective anti-acne therapy resulting in 
long-term remission and significant improvement in many patients. 
As reported by AAD, the use of oral isotretinoin is only 
recommended for severe AV or moderate AV as an alternative 
therapy [6]. 
This literature review was conducted to explain the mechanism of 
action, effectiveness, contraindications, side effects, and safety of oral 
isotretinoin in AV, which provided essential information for 
dermatologists. Articles were obtained from PubMed and Cochrane 
Central databases for published articles during the past 20 y. 
Keywords used for this review were ‘acne vulgaris’ and ‘isotretinoin’. 
Only articles written in English were included in this review.  
Pharmacokinetics  
Isotretinoin is a metabolite product of vitamin A and provitamin A 
carotenoids, which can be found in liver, milk, cheese, and green 
vegetables. Retinol (vitamin A) is absorbed in the gastrointestinal 
tract and metabolized into the retinal in the liver. Furthermore, 
retinal will be oxidized to retinoic acid and can be converted to one 
another. The two isomers (retinoic acid and 13-cis-retinoic 
acid/isotretinoin) have identical chemical structures but different 
molecular geometry, resulting in different half-life; approximately 
20 h for isotretinoin and 0.9 h for retinoic acid. Isotretinoin and 
retinoic acid are further metabolized to oxo-isotretinoin and oxo-
retinoic acid, respectively. Like other retinoates, isotretinoin’s 
lipophilic characteristic leads to a wide range of absorption levels 
when consumed without food. When taking them with food, the 
bioavailability (measured as mean maximum plasma concentration 
and the area under the ‘plasma concentration-time’ curve) increases, 
and the variability decreases [9, 10]. 
Isotretinoin is strongly bound (>95%) to plasma protein, mostly 
albumin, and is not stored in adipose tissue. This has been 
scientifically proven by direct measurement of isotretinoin in 
plasma, skin, and subcutis. The concentration of isotretinoin in the 
skin and subcutis are lower than in plasma. In acne patients treated 
with oral isotretinoin, the concentration of approximately 60 ng/g 
and 40 ng/g were found in the epidermis and subcutis, respectively, 
compared to 100 ng/ml in plasma [10]. 
A study was conducted on acne patients using a high-performance 
liquid chromatography assay [11]. Fig. 1 shows the plasma 
concentration of isotretinoin, retinoic acid, and their metabolites in 
the last 4 w of therapy with isotretinoin at an oral dose of 30 
mg/day. During therapy, stable concentrations of oxo-isotretinoin 




Fig. 1: Mean plasma concentrations of isotretinoin and its metabolite at the last 4 w of treatment (days 28 to 0) with oral isotretinoin (oral 
dose of 30 mg/day), and at 6 w after completion of therapy (days 0 to 42) [10, 11] 
 
Table 2 below shows some pharmacokinetic parameters of 
isotretinoin obtained from studies in patients with acne, while data 
on retinoic acid were collected from studies in healthy individuals 
receiving retinoic acid [10, 12]. 
 
Table 2: Pharmacokinetic parameters of isotretinoin and its metabolites 
 Isotretinoin Oxo-isotretinoin Retinoic acid* Ref 
Half-life (d) 18.7±6.2 29.2±5.7 0.9±0.4 [10] 
Cmax (ng/ml) 208±91.8 473.2±171.3 22.4±15.0  
Cmin (ng/ml) 89.9±48.7 387.9±152.1 11.2±5.6  
Tmax (d) 4.5±3.4 6.8±6.5 4.5±3.3  
*Pharmacokinetic parameters when all-trans retinoic acid is administered directly to patients  
 
Isotretinoin has been reported to have several interactions with 
other drugs, such as alcohol, fungistatic imidazole, salicylic acid, 
indomethacin, carbamazepine, oral tetracycline, and vitamin A 
[8]. 
A literature reported a decline of efficacy when isotretinoin is taken 
together with large amounts of alcohol. Also, its concentration will 
increase if combined with fungistatic imidazole [8]. This occurs due 
to the metabolism of isotretinoin by the enzyme cytochrome P450, 
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in which ethanol is its inducer. As a result, the metabolism of 
isotretinoin increases while its efficacy decreases.  
In addition, the antifungal class of imidazole is an inhibitor of this 
isoenzyme, thus decreasing isotretinoin metabolism. Therefore, its 
concentration in the blood increases, provoking the risk of toxicity [8]. 
Isotretinoin is distributed in the blood bound to albumin. Its 
distribution will be disrupted if there is consumption of drugs that 
are acidic and have a high affinity for albumin; for instance, salicylic 
acid and indomethacin [8]. 
If these drugs concentrations are high enough in the blood, it can 
substitute isotretinoin from protein binding, thus increasing the 
amount of unbound drug concentration. Carbamazepine plasma level 
decreases when taken with isotretinoin. Hence, careful monitoring 
should be done in epileptic patients taking carbamazepine with 
isotretinoin. Combination of oral tetracycline and isotretinoin should 
be avoided since it may trigger intracranial hypertension. Lastly, 
supplements containing vitamin A should not be taken together with 
isotretinoin due to possible additive toxic effects [8]. 
Isotretinoin mechanism of action 
Isotretinoin is known to be the only treatment modality that has 
implications for the entire pathogenesis of acne. The mechanism of 
action of isotretinoin is mediated through its role in cell cycle and 
differentiation, immune function, and apoptosis [13-19]. 
Retinoid plays a role through nuclear interactions with retinoic acid 
receptors (RARs), which are ligand-dependent transcription factors. 
In other words, the regulation of gene transcription solely occurs 
through the interaction of retinoid composition with the receptors. 
These receptors can be activated from various retinoid forms, their 
metabolites, and isomers with differences in binding affinity. RARs 
bind to 9-cis-trans-retinoic acid and two major natural vitamin A 
derivatives, whereas retinoid x receptors (RXRs) only bind to 9-cis-
trans-retinoic acid. Retinoid can induce or suppress the expression 
of various genes and play an essential role in the cellular process. 
The mechanism of action includes normalizing follicular 
hyperkeratinization, decreasing the production of cytokeratin 1, 10, 
14, filaggrin, matrix metallopeptidases (MMPs), and toll-like 
receptor 2 (TLR-2), and increasing the production of cytokeratin 7, 
13, 19, laminina B1, and IL-1 [9, 20]. 
Therefore, retinoid contributes to decreasing corneocytes’ adhesion, 
supporting cellular proliferation and follicular renewal, induction of 
cell apoptosis, and immune regulation [9]. 
Through these mechanisms, isotretinoin may alter comedogenesis, 
decrease sebum production and colonization of Propionibacterium 
acnes, and promote anti-inflammatory effects [8]. Isotretinoin affects 
comedogenesis by reducing hyperkeratinization through a 
mechanism that is still unknown [21-23]. To date, there is still no 
evidence proving the effects of isotretinoin on keratinocyte 
metabolism [3]. Furthermore, it is known that isotretinoin does not 
have a direct antimicrobial mechanism. Isotretinoin lessens the rate 
of sebum excretion and the size of pilosebaceous ducts, making the 
skin environment less favorable for P. acnes. In addition, isotretinoin 
can also improve host defense mechanisms and modify chemotaxis 
monocytes to produce anti-inflammatory effects. The significant 
reduction in P. acnes population also contributes to the decline in 
acne inflammation [8]. 
Effectiveness of AV therapy with isotretinoin  
Initially, isotretinoin is only indicated for nodulocystic AV cases. 
However, it is recently used for moderate to severe AV that does not 
respond well to topical combination therapy or systemic antibiotics 
[24]. Table 3 outlines some of the results from clinical trials of 
isotretinoin.
  
Table 3: Effectiveness of AV therapy with isotretinoin in various studies 
 
 






















2013 75 patients with 







For 7 d in 1 mo Acne lesion 
count, total 





side effects  
Both regimens 




regimen can be 
cost-effective 
alternatives. 






2005 60 patients with 
mild to 
moderate AV  
0,5-0,75/kg 
per day for 1 
w out of 4 w  
6 mo Acne severity 




safe and effective 
for mild to 
moderate AV. 
All side effects are 
mild; there is no need 
for drug 
discontinuation. 














6 mo  Low dose 
isotretinoin for 6 
mo is effective 
for moderate 
acne, minimal 
side effects, and 
lower cost 
compared to 
higher dose.  
Cheilitis (91%), mild 
xerosis (43%), 
epistaxis (2,5%), 
elevated liver enzymes 
(4.85), elevated serum 
lipids (4.2%). 
1B [27] 
4 Shetti et 
al. 
2017 100 patients 
with moderate 
to severe AV  
Group 1: 20 
mg of 
isotretinoin 
once a day  
Group 2: 20 
mg of 
isotretinoin 
once a day for 
7 d out of 1 
mo  









between group 1 
and 2. 
- 1C [24] 
5 Costa et al.  2019 3836 
patients 
with 
Group 1: oral 
isotretinoin  
Group 2: oral 
Minimum 
period of 16 w 
Decreased 
inflammatory 
lesion count  
87 per 100 
comparative risk 
(with 95% Cl). 
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moderate to 
severe AV  
antibiotic  For oral 
antibiotics with 
other topical 
agents, 86 per 
100.  
6 Akman et al. 2007 66 patients 
with 
moderate to 
severe AV  
0,5 
mg/kg/day 








is effective in 
both regular and 
intermittent 
doses.  
Side effects are minor 




2014 Mild acne Low dose 
isotretinoin 
(5 mg/day) 




16-32 w is very 
effective for 
adult AV.  
Good safety profile, 
indicated by mild side 
effects, mostly mild 
and short-lived 
dryness of mucous 
membrane. 
1A [7] 










12 mo  Excellent 
therapeutic 
response of more 
than 80%. 
 1A1 [30] 
Most of the patients receiving oral isotretinoin were acne-free after 4-6 mo of treatment, depending on the dose. Recent clinical experience suggests 
that long-term recovery rates can be lower than previously thought [31-34].  
 
Contraindication 
Contraindications for isotretinoin include pregnancy, breastfeeding, 
hepatic dysfunction, uncontrolled hyperlipidemia, hypervitaminosis 
A, and renal insufficiency [35]. Isotretinoin falls into Category X drugs 
and should not be taken by patients who are pregnant or who may 
become pregnant. Isotretinoin has been reported to cause severe 
congenital abnormalities. In 2005, The Food and Drug Administration 
issued a recommendation in the US for both women and men taking 
oral isotretinoin to be registered on the national ‘iPLEDGE’ program. 
As a mandatory regulatory program in the United States, the ‘iPLDGE’ 
program needs to be completed prior to distributing isotretinoin to 
prevent the use of this drug during pregnancy to prevent 
teratogenicity [36]. This requirement is aimed at women of 
reproductive age with regulations as follows: two negative pregnancy 
tests prior to prescription, negative pregnancy test every month for 
each isotretinoin prescription, and documented abstinence or use of 
contraception. Moreover, signature confirmation is required to 
confirm that patients have fully understood the possible adverse 
events such as depression and suicidal thoughts. Isotretinoin is also 
contraindicated in patients who are hypersensitive to its components, 
such as vitamin A and its preservatives [37, 38]. 
Side effects and monitoring 
Although isotretinoin may induce many side effects, they are 
predictable and rarely affect patient’s therapy. The reported side 
effects of oral isotretinoin range widely, from mucocutaneous effects, 
including dryness and cracking of lips and skin, to teratogenicity [39]. 
Isotretinoin may also impact the sebaceous glands and reduce gland 
activity, size, and decrease sebum production. Mucocutaneous effects 
from isotretinoin are dose-dependent and generally well tolerated 
with dosage modification and additional symptomatic therapy [8]. Dry 
oral mucosa can occur in almost any patient within a few days after 
initiation of treatment. Dry skin, facial patches, or irritation are 
reported in 1:5 patients and occur in the first 4 w when acne flares are 
frequently reported. Nasal dryness also occurs in 30-50% of patients. 
Nevertheless, mucocutaneous side effects can be controlled with the 
routine use of moisturizers [8, 40]. 
Excessive mucocutaneous dryness may lead to retinoid dermatitis, 
severe retinoid cheilitis, or conjunctivitis as complications from 
secondary S. aureus infection. These symptoms need to be treated 
with moderate to strong potency steroid ointment in combination 
with antiseptic. If impetiginization occurs, anti-staphylococcal 
therapy such as mupirocin 2% ointment should be used [8]. If visual 
disturbances are present, patients should immediately discontinue 
the treatment and be examined by an ophthalmologist [27]. 
The most fatal adverse event that may occur is teratogenicity. 
Clinicians need to inquire pregnancy plans in individuals taking 
isotretinoin and provide informed consent [8]. 
Taking isotretinoin 30 d before and during pregnancy has been reported 
to cause fetal or neonatal problems (above 16 w of gestation), such as 
fetal death in the uterus, congenital birth defects, and neural tube defects. 
Congenital anomalies include abnormalities of the skin, abdominal wall, 
cardiovascular, digestive, nervous, musculoskeletal, respiratory, and 
urogenital system, as well as multiple chromosomal anomalies/ 
syndromes and other congenital malformations [41, 42]. 
Mood changes and depression are also common in patients taking 
isotretinoin. A cross-over controlled case study demonstrated a 2.68 
relative risk of depression (95% CI: 1,03 to 3,89) for acne patients 
taking oral isotretinoin. However, this report is still considered 
contradictory to other studies. Therefore, mood changes and 
depression symptoms are required to be asked and monitored in 
every visit [8]. Due to the possibility of developing cerebral 
pseudotumor, isotretinoin is contraindicated when combined with 
many other medications, including tetracycline. Tetracycline, including 
doxycycline and minocycline, must not be prescribed with isotretinoin 
as both drugs can cause intracranial hypertension. Headache can be 
one of the prodromal symptoms. Systemic side effects generally can be 
repressed by decreasing dosage and using NSAIDs or aspirin [8]. 
 
Table 4: The prevalence of frequent side effects by dose (absolute number and percentage of patients by dose groups) 
Side effects Number of patients (%) Ref 
Infection 
Abnormal serum lipid 
Others 
Late response to treatment 
Periungual granuloma 
Significantly abnormal liver function  
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Acute flare during the initial use of isotretinoin may occur in 6% of 
cases, with predisposing risk factors including macro comedones 
and nodules. Flare can be very severe and cause physical and 
psychological limitations. If flare develops, oral prednisolone should 
be prescribed at a dose of 0.5-1 mg/kg/day for 2-3 w and can be 
tapered off slowly over 6 w. In addition, isotretinoin consumption 
needs to be discontinued or use a dose of 0.25 mg/kg/day, 
depending on the severity [8]. 
Results from a retrospective study of 1743 participants that 
evaluated the prevalence of isotretinoin side effects are shown in 
table 4 and table 5 [43]. 
 
Table 5: Other side effects 
 Dosage 
 Very low (0-0.25) 
N = 450 (%) 
Low (0.26-0.50) 
N = 471 (5) 
Medium (0.51-0.75) 
N = 119 
High (0.76-1.0) 
N = 703 (%) 
Total 




















































Due to the various side effects that might arise, further clinical and 
laboratory assessments are needed to monitor response to therapy 
and the safety of oral isotretinoin. The need to monitor serum 
transaminase, liver function, and serum lipid during therapy is still 
under debate. Elevation of these tests occurred in almost all patients, 
and they quickly returned to initial levels as soon as therapy was 
terminated. Nevertheless, it is important to conduct these tests 
before therapy is initiated. Previous studies have stated it is 
unnecessary to repeat laboratory tests during treatment, except in 
high-risk populations such as patients with diabetes and familial 
hypertriglyceridemia. However, the European Directive 
recommended assessing liver enzyme tests and lipid profile at 
baseline, at 1 mo, and 3 mo after initiation of therapy [8]. Monitoring 
of triglyceride level is conducted specifically to avoid the incidence 
of pancreatitis correlated with hypertriglyceridemia, although it 
does not often occur [44]. Prior to therapy, assessments include liver 
function tests, fasted lipid profile (including triglyceride level), blood 
glucose, creatinine, and complete blood count with differential 
counts. Screening for mood changes, psychosis, aggression, suicidal 
thoughts, skin changes, and visual changes can also be conducted 
prior to therapy [23, 24]. 
It is important to list down the components that need to be 
evaluated before therapy, evaluations that need to be repeated 
during therapy, and the frequency or intervals for conducting those 
evaluations. It could all be written down on one table and be given a 
subtitle “side effects”. For example, as isotretinoin can disrupt fat 
metabolism, it is essential to assess lipid profile prior to therapy. 
Evaluations needed prior to and during oral isotretinoin therapy are 
written in the table below (table 6). 
  
Table 6: Evaluations needed prior to and during oral isotretinoin therapy 
Evaluation Prior to therapy 1 mo after therapy started 3 mo after therapy started 
Complete blood count √   
Blood glucose √   
Creatinine √   
Liver function √ √ √ 
Lipid profile √ √ √ 
Mood changes √ √ √ 
 
The consequences of this strict regulation may decrease the use of 
isotretinoin, which may be a disadvantage for patients that actually 
need this therapy. On the other side, restriction of isotretinoin use as 
a second-line therapy can lead to acne scar formation that could 
affect the quality of life.  
Expert opinion backed by clinical data supported the use of 
isotretinoin for acne vulgaris patients with moderate severity 
that for any reason did not respond to conventional therapy. 
Acne can lead to scarring in 30% of acne with moderate 
severity and significant psychological morbidity in 12-13% of 
cases [8, 45]. 
CONCLUSION 
Isotretinoin is one of the treatment modalities for acne with 
good effectivity and has been used as standard acne 
management in many countries due to its mechanism of actions 
that affect the entire acne pathogenesis. Considering the 
various side effects of isotretinoin ranging from mild to severe, 
its use requires adequate clinical assessment and monitoring 
by a dermatologist.  
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